News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • Study led by Dr. Jennifer Ligibel finds exercise programs can improve quality of life for cancer survivors.

Tags: BreastCancer, Nutrition

  • On June 1st, Dana-Farber Community Cancer Care (DFCCC) will begin providing oncology services at Holy Family Hospital in Methuen.

Tags: Partnerships

  • In a new study published in Nature, Dana-Farber scientists demonstrate how a sudden, isolated shuffling of genetic material — known as chromothripsis — can occur.

Tags: BasicResearch, Genomics

  • First study of the genomic composition of prostate cancer shows many patients have gene mutations that can be targeted with existing or potential drugs.

Tags: Genomics, ProstateCancer, TargetedTherapy

  • A new technology developed at Dana-Farber may make it possible to target "undruggable" proteins and overcome drug resistance by using a cancer cell's own protein-degrading machinery to destroy, not just inhibit, cancer proteins.

Tags: BasicResearch, TargetedTherapy

  • Dana-Farber/Brigham and Women's Cancer Center has a new website to connect patients and physicians with information about precision cancer medicine, including resources on what precision cancer is and how it can be applied to cancer care today.

Tags: BasicResearch, Genomics

  • Dana-Farber's Levi Garraway, MD, PhD, has been selected as one of 26 Howard Hughes Medical Institute investigators.

Tags: Genomics, Honors, ProstateCancer

  • Researchers from Dana-Farber Cancer Institute will be presenting more than 70 studies at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 29 – June 2, 2015.

Tags: chemotherapy, BreastCancer

  • New findings led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center show informing parents about their child’s cancer prognosis – even when the prognosis is less than favorable – is much more likely to give parents peace of mind and hope rather than increase their anxiety or cause them to become depressed.

Tags: ChildhoodCancer

  • Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination according to a new study led by scientists at Dana-Farber Cancer Institute,

Tags: TargetedTherapy

Showing 11-20 of 611 items